

# ImmunoPrecise Antibodies Ltd

08:06 04 Apr 2019

## ImmunoPrecise Antibodies Ltd uplists to OTCQB Venture market from Pink Sheets

Shares of ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) will kick off trading Thursday on the OTCQB Venture market after uplisting from the more speculative Pink Sheets.

The move will allow the Canadian antibody discovery firm to woo more US investors and boost its liquidity.

"As ImmunoPrecise gains recognition for its best-in-class full-service, therapeutic antibody discovery company, we are experiencing increased interest from investors across North America and other International markets," said Lisa Hebling, chief financial officer.

**READ:** ImmunoPrecise Antibodies shares up as it launches new antibody discovery platform with US pharma group

"Our listing on the OTCQB allows for better access to the U.S. investment community, greater international visibility, and improved liquidity," Hebling added.

The British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.

**READ:** ImmunoPrecise Antibodies sees 56% increase in 3Q revenue as it continues to advance business

The company's attention is fixed on discovering and delivering the most relevant next-generation antibodies, with the highest probability of succeeding through clinical validation.

It recently opened a new office in Cambridge, Massachusetts that will be staffed at first for sales and business development and will take advantage of the Cambridge area's focus on biotech and pharmaceuticals.


ImmunoPrecise closed at US\$0.58 in New York on Wednesday.

Contact Ellen Kelleher at [ellen@proactiveinvestors.com](mailto:ellen@proactiveinvestors.com)

**Price:** \$0.57

**Market Cap:** \$38.73 m

### 1 Year Share Price Graph



September 2018 March 2019 September 2019

### Share Information

**Code:** IPA

**Listing:** TSX-V

52 week	High	Low
	0.99	0.5

**Sector:** Pharma & Biotech

**Website:** [immunoprecise.com](http://immunoprecise.com)

### Company Synopsis:

*ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

## No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount 

up	to	Twenty	Five	Thousand	dollars	(\$25,000).
----	----	--------	------	----------	---------	-------------